TABLE 4.

Uni- and multivariate analysis of prognostic power of clinical characteristics and metabolic syndrome components in metastatic CRC patients.

Co-variate	Dicothomization	Median survivals (months)	No. of events/Patients	P at univariate	HR	95% CI	P at multivariate
Age	≥65 vs. <65 years	26.0 vs. 46.0	79/157 vs. 31/87	0.0641	1.44	0.97–2.14	0.0290
Gender	M vs. F	44.0 vs. 30.0	50/117 vs. 60/127	0.5736	0.89	0.61–1.31	0.7122
Side	L vs. R	46.0 vs. 32.0	70/151 vs. 40/93	0.2113	1.27	0.86–1.88	0.3271
Metastatic involvment	>1 vs. 1 site	33.0 vs. 28.0	44/81 vs. 66/163	0.0875	1.42	0.94–2.13	0.7863
Response to first-line CT	DC vs. no DC	46.0 vs. 15.0	62/154 vs. 36/62	<0.0001	0.34	0.20–0.56	<0.0001
KRAS mutations	Mutated vs. wild-type	30.0 vs. 42.0	65/134 vs. 45/110	0.0495	1.46	1.00–2.13	0.2993
T2D	Present vs. not present	12.0 vs. 42.0	32/50 vs. 78/194	0.0001	2.91	1.72–4.94	0.4165
BMI	≥25 kg/m2 vs. normal	22.0 vs. 45.0	64/120 vs. 46/124	0.0040	1.75	1.19–2.58	0.2054
HT	Present vs. not present	26.0 vs. 42.0	57/110 vs. 53/134	0.0838	1.40	0.95–2.06	0.5681
Cluster of T2D, BMI, HT	Present vs. not present	12.0 vs. 42.0	25/40 vs. 85/204	<0.0001	4.56	2.40–8.67	0.0217

CI, confidence interval; DC, disease control; F, female; HR, hazard ratio; L, left; M, male; R, right.